Oncopharmpod
Axi-Cel and 5-FU Label Changes
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:12:34
- Mas informaciones
Informações:
Sinopsis
We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)
